<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590547</url>
  </required_header>
  <id_info>
    <org_study_id>GLS27-005</org_study_id>
    <nct_id>NCT04590547</nct_id>
  </id_info>
  <brief_title>GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)</brief_title>
  <official_title>Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the&#xD;
      prevention of severe pneumonitis caused by SARS-CoV-2 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized, double-blind, placebo-controlled, study will assess 2 different&#xD;
      doses of GLS-1027 in the prevention of severe pneumonitis among those hospitalized with PCR&#xD;
      confirmed SARS-CoV-2 infection. Subjects will be randomized at a 1:1:1 ratio to either&#xD;
      Standard of Care (SOC) plus placebo, or SOC plus GLS-1027 at either 120 mg or 360 mg daily.&#xD;
      Clinical status will be monitored through 56 days from the initiation of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events relative to treatment group</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment failure at day 28 from enrollment</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days of hospitalization relative to treatment group</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days requiring ICU care relative to treatment group</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days of NIV, high-flow O2, or mechanical ventilation relative to treatment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for subjects who are intubated relative to treatment group.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days of PEEP &gt; 5 cm H2O for subjects who are intubated relative to treatment group</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in WHO Classification level at day 28 from enrollment</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Pneumonitis</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>GLS-1027 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-1027 360 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 120 mg pills of GLS-1027 given by mouth once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three Placebo pills given by mouth once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-1027</intervention_name>
    <description>GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.</description>
    <arm_group_label>GLS-1027 120 mg</arm_group_label>
    <arm_group_label>GLS-1027 360 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo looks like GLS-1027</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
          -  Able and willing to comply with study procedures&#xD;
&#xD;
          -  Diagnosis of PCR confirmed SARS-CoV-2&#xD;
&#xD;
          -  Enrollment within 72 of hospitalization&#xD;
&#xD;
          -  WHO COVID-19 classification level 3 or 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Need for mechanical ventilation, non-invasive ventilation (NIV), or high-flow O2&#xD;
             (≥60%) via face mask&#xD;
&#xD;
          -  Calculated GFR &lt; 60 (Cockcroft-Gault)&#xD;
&#xD;
          -  Meets treatment algorithm criteria for treatment with a non-study immune modulator&#xD;
&#xD;
          -  Pre-study or planned treatment with a non-study immune modulator&#xD;
&#xD;
          -  Participation in a COVID-19 clinical trial that includes prescription of a drug with&#xD;
             anti-cytokine activity&#xD;
&#xD;
          -  Status post transplantation of an organ, bone marrow, or body part&#xD;
&#xD;
          -  Treatment within the past 60 days with a chemotherapeutic agent&#xD;
&#xD;
          -  Diagnosis of leukemia or lymphoma&#xD;
&#xD;
          -  WHO COVID-19 classification level of 5 or greater&#xD;
&#xD;
          -  Unable to take oral medication&#xD;
&#xD;
          -  Grade 3 or greater laboratory abnormalities as characterized by CTCAE v5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>610-707-5671</phone>
    <email>jmaslow@genels.us</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Project Manager</last_name>
    <email>dkane@genels.us</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baton Rouge General Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>PHI Clinical Hospital - Shtip, Department for Infectious Diseases and Febrile Conditions</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dragica Timova</last_name>
    </contact>
    <investigator>
      <last_name>Dijana Shishkova Gajdardziska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PHI General City Hospital &quot;8mi Septemvri&quot; - COVID-19 Intensive Care Department</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maja Duganovska</last_name>
    </contact>
    <investigator>
      <last_name>Daniela Buklioska Ilievska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PHI University Clinic for Pulmonology and Allergology</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitar Karkinski</last_name>
    </contact>
    <investigator>
      <last_name>Dejan Dokic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PHI University Clinic of Infectious Diseases and Febrile Conditions</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilir Demiri</last_name>
    </contact>
    <investigator>
      <last_name>Milena Stevanovikj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PHI General Hospital Struga bb, Quay &quot;8-mi Noemvri&quot;</name>
      <address>
        <city>Struga</city>
        <country>North Macedonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xhumkar Shpendi</last_name>
    </contact>
    <investigator>
      <last_name>Mira Kostojchinoska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Davila Neves</last_name>
      <phone>787-767-9192</phone>
      <email>sylvia.davila1@upr.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Santana Bagur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>North Macedonia</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

